Joshua Burke
No ORCID on file
· 6 papers in corpus
· active 2009-2015
Study types
- article 6
Condition tags
- endometriosis 6
- chronic_pelvic_pain 2
- dysmenorrhea 1
- dyspareunia 1
Top journals
Frequent coauthors
- Roland Jimenez 6
- Chris O’Brien 6
- Kristof Chwalisż 5
- Ping Jiang 5
- Bruce R. Carr 4
- Dmowski WP 3
- Carr B 3
- Burke J 3
- Jiang P 3
- Elizabeth Garner 3
article
2015
Purpose Elagolix is a novel, oral GnRH antagonist that dose-dependently suppresses estradiol levels. This study evaluated safety and efficacy of elagolix vs. leuprorelin acetate (LA) and placebo in women with endometriosis-associated pain. …
article
2014
This randomized double-blind study, with 24-week treatment and 24-week posttreatment periods, evaluated the effects of elagolix (150 mg every day, 75 mg twice a day) versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on bone mi…
article
2013
OBJECTIVE: The aim of this study was to estimate the efficacy of elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of endometriosis-associated pelvic pain. METHODS: This was a phase II, randomized, placeb…
article
2013
This Phase 2 study evaluated the safety and efficacy of elagolix for treating endometriosis-associated pain. A total of 155 women with laparoscopically confirmed endometriosis were randomized to placebo, elagolix 150 mg, or elagolix 250 mg …
article
2011
article
2009